Acquisition history Custopharm has a recent acquisition by Hikma Pharmaceuticals for 375 million with milestones, indicating strong validation of its sterile injectable platform and potential access to Hikma's global sales network.

Product portfolio With more than 30 products and a focus on high barrier sterile injectables, there are opportunities to cross-sell into existing Hikma customers and expand into adjacent sterile categories.

Market positioning Positioned as a U.S. leader in generic injectables at an early commercial stage, presenting a near-term window for accelerated scale through partnerships, licenses, and contract manufacturing opportunities.

Customer reach Serving over 100 organizations in the pharmaceutical industry suggests a broad network for channel partnerships, co-development deals, and distribution arrangements across generics and sterile products.

Growth levers Strategic investor backing and Leucadia Pharmaceuticals alignment imply access to capital, mentorship, and potential collaboration on new product development, regulatory pathways, and commercialization strategies.